chr2-240868891-C-A

Variant summary

Our verdict is Benign. The variant received -17 ACMG points: 3P and 20B. PM1PP2BP4_StrongBP6_Very_StrongBS1BS2

The NM_000030.3(AGXT):​c.26C>A​(p.Thr9Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00888 in 1,611,766 control chromosomes in the GnomAD database, including 80 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. T9T) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0071 ( 6 hom., cov: 33)
Exomes 𝑓: 0.0091 ( 74 hom. )

Consequence

AGXT
NM_000030.3 missense

Scores

18

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts U:1B:10

Conservation

PhyloP100: 0.775
Variant links:
Genes affected
AGXT (HGNC:341): (alanine--glyoxylate aminotransferase) This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -17 ACMG points.

PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 6 uncertain in NM_000030.3
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 130 curated pathogenic missense variants (we use a threshold of 10). The gene has 12 curated benign missense variants. Gene score misZ: -0.26789 (below the threshold of 3.09). Trascript score misZ: -0.48778 (below the threshold of 3.09). GenCC associations: The gene is linked to primary hyperoxaluria type 1, alanine glyoxylate aminotransferase deficiency.
BP4
Computational evidence support a benign effect (MetaRNN=0.007460147).
BP6
Variant 2-240868891-C-A is Benign according to our data. Variant chr2-240868891-C-A is described in ClinVar as [Likely_benign]. Clinvar id is 204016.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00709 (1079/152088) while in subpopulation NFE AF = 0.0105 (711/67944). AF 95% confidence interval is 0.00983. There are 6 homozygotes in GnomAd4. There are 504 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position FAILED quality control check.
BS2
High Homozygotes in GnomAd4 at 6 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
AGXTNM_000030.3 linkc.26C>A p.Thr9Asn missense_variant Exon 1 of 11 ENST00000307503.4 NP_000021.1 P21549

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
AGXTENST00000307503.4 linkc.26C>A p.Thr9Asn missense_variant Exon 1 of 11 1 NM_000030.3 ENSP00000302620.3 P21549
AGXTENST00000472436.1 linkn.46C>A non_coding_transcript_exon_variant Exon 1 of 5 2

Frequencies

GnomAD3 genomes
AF:
0.00711
AC:
1080
AN:
151974
Hom.:
6
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00191
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00446
Gnomad ASJ
AF:
0.0176
Gnomad EAS
AF:
0.000386
Gnomad SAS
AF:
0.00436
Gnomad FIN
AF:
0.0119
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0105
Gnomad OTH
AF:
0.00478
GnomAD2 exomes
AF:
0.00919
AC:
2204
AN:
239930
AF XY:
0.00945
show subpopulations
Gnomad AFR exome
AF:
0.00157
Gnomad AMR exome
AF:
0.00639
Gnomad ASJ exome
AF:
0.0130
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0135
Gnomad NFE exome
AF:
0.0120
Gnomad OTH exome
AF:
0.0169
GnomAD4 exome
AF:
0.00906
AC:
13227
AN:
1459678
Hom.:
74
Cov.:
31
AF XY:
0.00908
AC XY:
6596
AN XY:
726058
show subpopulations
Gnomad4 AFR exome
AF:
0.00132
AC:
44
AN:
33434
Gnomad4 AMR exome
AF:
0.00624
AC:
278
AN:
44586
Gnomad4 ASJ exome
AF:
0.0129
AC:
336
AN:
26104
Gnomad4 EAS exome
AF:
0.00
AC:
0
AN:
39638
Gnomad4 SAS exome
AF:
0.00669
AC:
575
AN:
85978
Gnomad4 FIN exome
AF:
0.0133
AC:
695
AN:
52432
Gnomad4 NFE exome
AF:
0.00961
AC:
10685
AN:
1111424
Gnomad4 Remaining exome
AF:
0.00879
AC:
530
AN:
60322
Heterozygous variant carriers
0
822
1643
2465
3286
4108
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Exome Hom
Variant carriers
0
358
716
1074
1432
1790
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00709
AC:
1079
AN:
152088
Hom.:
6
Cov.:
33
AF XY:
0.00678
AC XY:
504
AN XY:
74354
show subpopulations
Gnomad4 AFR
AF:
0.00190
AC:
0.00190343
AN:
0.00190343
Gnomad4 AMR
AF:
0.00445
AC:
0.00445084
AN:
0.00445084
Gnomad4 ASJ
AF:
0.0176
AC:
0.0175995
AN:
0.0175995
Gnomad4 EAS
AF:
0.000387
AC:
0.000386847
AN:
0.000386847
Gnomad4 SAS
AF:
0.00436
AC:
0.00436409
AN:
0.00436409
Gnomad4 FIN
AF:
0.0119
AC:
0.0118913
AN:
0.0118913
Gnomad4 NFE
AF:
0.0105
AC:
0.0104645
AN:
0.0104645
Gnomad4 OTH
AF:
0.00426
AC:
0.00426136
AN:
0.00426136
Heterozygous variant carriers
0
61
122
183
244
305
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00913
Hom.:
22
Bravo
AF:
0.00649
ESP6500AA
AF:
0.00159
AC:
7
ESP6500EA
AF:
0.00930
AC:
80
ExAC
AF:
0.00968
AC:
1173
Asia WGS
AF:
0.00375
AC:
13
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Uncertain:1Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Primary hyperoxaluria, type I Uncertain:1Benign:3
Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 27, 2014
Clinical Biochemistry Laboratory, Health Services Laboratory
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:in vitro

- -

Feb 13, 2018
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -

May 28, 2019
Mendelics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:4
Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Nov 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

AGXT: BP4, BS2 -

Dec 04, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 28969594, 27884173, 15849466, 21228398, 20981092, 17495019) -

not specified Benign:3
Sep 17, 2015
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: ExAC frequency -

Dec 18, 2021
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.081
BayesDel_addAF
Benign
-0.46
T
BayesDel_noAF
Benign
-0.42
CADD
Benign
4.9
DANN
Benign
0.84
DEOGEN2
Benign
0.18
T
Eigen
Benign
-1.3
Eigen_PC
Benign
-1.3
FATHMM_MKL
Benign
0.19
N
LIST_S2
Benign
0.32
T
MetaRNN
Benign
0.0075
T
MetaSVM
Benign
-0.56
T
MutationAssessor
Benign
0.55
N
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-1.0
N
REVEL
Benign
0.26
Sift
Benign
0.045
D
Sift4G
Benign
0.18
T
Polyphen
0.0010
B
Vest4
0.69
MVP
0.46
MPC
0.036
ClinPred
0.0012
T
GERP RS
1.4
Varity_R
0.11
gMVP
0.73
Mutation Taster
=89/11
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs115014558; hg19: chr2-241808308; API